Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 155

1.

JAK-STAT and G protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma.

Nairismägi ML, Tan J, Lim JQ, Nagarajan S, Ng CC, Rajasegaran V, Huang D, Lim WK, Laurensia Y, Wijaya GC, Li ZM, Cutcutache I, Pang WL, Thangaraju S, Ha J, Khoo LP, Chin ST, Dey S, Poore G, Tan LH, Koh HK, Sabai K, Rao HL, Chuah KL, Ho YH, Ng SB, Chuang SS, Zhang F, Liu YH, Pongpruttipan T, Ko YH, Cheah PL, Karim N, Chng WJ, Tang T, Tao M, Tay K, Farid M, Quek R, Rozen SG, Tan P, Teh BT, Lim ST, Tan SY, Ong CK.

Leukemia. 2016 Feb 8. doi: 10.1038/leu.2016.13. [Epub ahead of print]

PMID:
26854024
2.

Management of relapsed multiple myeloma: Recommendations of the international myeloma working group.

Laubach J, Garderet L, Mahindra A, Gahrton G, Caers J, Sezer O, Voorhees P, Leleu X, Johnsen HE, Streetly M, Ludwig H, Mellqvist UH, Chng WJ, Pilarski L, Einsele H, Hou J, Turesson I, Zamagni E, Chim J, Mazumder A, Westin J, Lu J, Reiman T, Kristinsson S, Joshua D, Roussel M, O'Gorman P, Terpos E, Dimopoulos M, Moreau P, Anderson K, Palumbo A, Kumar S, Rajkumar V, Durie B, Richardson P.

Leukemia. 2015 Dec 29. doi: 10.1038/leu.2015.356. [Epub ahead of print] Review.

PMID:
26710887
3.

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR investigators.

Lancet Oncol. 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. Epub 2015 Dec 5.

PMID:
26671818
4.

Gene signature combinations improve prognostic stratification of multiple myeloma patients.

Chng WJ, Chung TH, Kumar S, Usmani S, Munshi N, Avet-Loiseau H, Goldschmidt H, Durie B, Sonneveld P.

Leukemia. 2015 Dec 16. doi: 10.1038/leu.2015.341. [Epub ahead of print]

PMID:
26669975
5.

High-Throughput Mutation Profiling Changes before and 3 Weeks after Chemotherapy in Newly Diagnosed Breast Cancer Patients.

Tan SH, Sapari NS, Miao H, Hartman M, Loh M, Chng WJ, Iau P, Buhari SA, Soong R, Lee SC.

PLoS One. 2015 Dec 2;10(12):e0142466. doi: 10.1371/journal.pone.0142466. eCollection 2015.

6.

PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms.

Li XL, Zhou J, Chan ZL, Chooi JY, Chen ZR, Chng WJ.

Oncotarget. 2015 Nov 3;6(34):36689-99. doi: 10.18632/oncotarget.5385.

7.

Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse.

Garg M, Nagata Y, Kanojia D, Mayakonda A, Yoshida K, Haridas Keloth S, Zang ZJ, Okuno Y, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Ding LW, Alpermann T, Sun QY, Lin DC, Chien W, Madan V, Liu LZ, Tan KT, Sampath A, Venkatesan S, Inokuchi K, Wakita S, Yamaguchi H, Chng WJ, Kham SK, Yeoh AE, Sanada M, Schiller J, Kreuzer KA, Kornblau SM, Kantarjian HM, Haferlach T, Lill M, Kuo MC, Shih LY, Blau IW, Blau O, Yang H, Ogawa S, Koeffler HP.

Blood. 2015 Nov 26;126(22):2491-501. doi: 10.1182/blood-2015-05-646240. Epub 2015 Oct 5.

PMID:
26438511
8.

Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study.

Gupta N, Goh YT, Min CK, Lee JH, Kim K, Wong RS, Chim CS, Hanley MJ, Yang H, Venkatakrishnan K, Hui AM, Esseltine DL, Chng WJ.

J Hematol Oncol. 2015 Sep 4;8:103. doi: 10.1186/s13045-015-0198-1.

9.

MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib.

Xie Z, Bi C, Chooi JY, Chan ZL, Mustafa N, Chng WJ.

Leukemia. 2015 Dec;29(12):2347-54. doi: 10.1038/leu.2015.169. Epub 2015 Jun 30.

PMID:
26196464
10.

Necrotizing Fasciitis in Hematological Patients: Enterobacteriaceae Predominance and Limited Utility of Laboratory Risk Indicator for Necrotizing Fasciitis Score.

Foo RM, Tung ML, Poon LM, Chan D, Smitasin N, Koh LP, Chng WJ, Chai LY.

Open Forum Infect Dis. 2015 Jun 12;2(2):ofv081. doi: 10.1093/ofid/ofv081. eCollection 2015 Apr.

11.

Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma.

Bi C, Chung TH, Huang G, Zhou J, Yan J, Ahmann GJ, Fonseca R, Chng WJ.

Oncotarget. 2015 Sep 22;6(28):26508-18. doi: 10.18632/oncotarget.4769.

12.

Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose.

Venkatakrishnan K, Kim TM, Lin CC, Thye LS, Chng WJ, Ma B, Chen MH, Zhou X, Liu H, Kelly V, Kim WS.

Invest New Drugs. 2015 Aug;33(4):942-53. doi: 10.1007/s10637-015-0258-y. Epub 2015 Jun 19.

PMID:
26084989
13.

MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma.

Kong LR, Chua KN, Sim WJ, Ng HC, Bi C, Ho J, Nga ME, Pang YH, Ong WR, Soo RA, Huynh H, Chng WJ, Thiery JP, Goh BC.

Mol Cancer Ther. 2015 Jul;14(7):1750-60. doi: 10.1158/1535-7163.MCT-15-0062. Epub 2015 May 4.

PMID:
25939760
14.

Functional Characterization of D9, a Novel Deazaneplanocin A (DZNep) Analog, in Targeting Acute Myeloid Leukemia (AML).

Jiang X, Lim CZ, Li Z, Lee PL, Yatim SM, Guan P, Li J, Zhou J, Pan J, Chng WJ, Chai CL, Yu Q.

PLoS One. 2015 Apr 30;10(4):e0122983. doi: 10.1371/journal.pone.0122983. eCollection 2015.

15.
16.

Clonal hematopoiesis and blood-cancer risk.

Yan B, Ban K, Chng WJ.

N Engl J Med. 2015 Mar 12;372(11):1071. doi: 10.1056/NEJMc1500684#SA1. No abstract available.

PMID:
25760362
17.

Bimodal Influence of Vitamin D in Host Response to Systemic Candida Infection-Vitamin D Dose Matters.

Lim JH, Ravikumar S, Wang YM, Thamboo TP, Ong L, Chen J, Goh JG, Tay SH, Chengchen L, Win MS, Leong W, Lau T, Foo R, Mirza H, Tan KS, Sethi S, Khoo AL, Chng WJ, Osato M, Netea MG, Wang Y, Chai LY.

J Infect Dis. 2015 Aug 15;212(4):635-44. doi: 10.1093/infdis/jiv033. Epub 2015 Jan 22.

PMID:
25612733
18.

Plasma cell neoplasms: genetics, pathobiology, and new therapeutic strategies.

Lee DS, Chng WJ, Shimizu K.

Biomed Res Int. 2014;2014:941820. doi: 10.1155/2014/941820. Epub 2014 Dec 28. No abstract available.

19.

P53 mutations in colorectal cancer - molecular pathogenesis and pharmacological reactivation.

Li XL, Zhou J, Chen ZR, Chng WJ.

World J Gastroenterol. 2015 Jan 7;21(1):84-93. doi: 10.3748/wjg.v21.i1.84. Review.

20.

Prognostic implication of morphology, cyclinE2 and proliferation in EBV-associated T/NK lymphoproliferative disease in non-immunocompromised hosts.

Ng SB, Ohshima K, Selvarajan V, Huang G, Choo SN, Miyoshi H, Wang S, Chua HC, Yeoh AE, Quah TC, Koh LP, Tan PL, Chng WJ.

Orphanet J Rare Dis. 2014 Dec 5;9:165. doi: 10.1186/s13023-014-0165-x.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk